|
|
| Mirena
Cycle Control, |
|
| Safety, and Tolerability |
|
|
|
|
|
|
|
|
|
| n | Requires
clinician visit for initiation and |
||||||
| discontinuation |
|||||||
| n | Early spotting |
||||||
| n | Significant
reduction in menstrual blood loss and |
||||||
| high rate of
amenorrhea |
|||||||
| n | High rates of
continuation |
||||||
|
|
| Hidalgo M,
et al. Contraception. 2002;65:129-132. |
|
| Lahteenmaki P, et al.
Steroids. 2000;65:693-697. |
|
